Precision microbiome company, Microba Life Sciences, has welcomed business professional and molecular biologist Dr Jean-Philippe Laine as US Director of Business Development to drive forward partnerships in microbiome research, product and biomarker discovery and interventional trials.
With more than 13 years’ experience in the consultative selling of technologies and services in genomics and metabolomics biomarker discovery and (pre)/clinical development, Dr Laine’s expertise is invaluable to Microba’s global operations.
His extensive work leading business development, a previous role at Diversigen and strong scientific background in microbiome science provides him with a unique set of skills that will assist clients worldwide.
Dr Laine’s expertise makes him well placed to work with partners across product and biomarker discovery and interventional trials, with a focus on novel discoveries and utilising precision microbiome analysis to advance medicine.
“After several years in the microbiome services space, I firmly believe that Microba has a truly unique and differentiated platform and offering.”US Director of Business Development, Dr Jean-Philippe Laine.
“I’m excited to be part of this extraordinary, world-class team and to help our customers take the microbiome, and its potential to revolutionise human health, to the next level.”
In this US-based role, Dr Laine will focus on growing Microba’s footprint, market intelligence and new services expansion in the US, which has an estimated microbiome testing market of $21.5b which accounts for 52.1 per cent of the global market.
Microba Life Sciences CEO, Dr Luke Reid, said that Dr Laine’s unique knowledge of the US microbiome research, biomarker and product discovery market would add significant value to Microba’s operations.
“I am delighted to welcome Dr Laine into the Microba team,” he said.
“Dr Laine has joined us with a true understanding of the technology we have developed, and how it can be used to create solutions for our partners.
“He has extensive experience in the field and is ideally placed to represent the quality and utility of our capabilities to biopharma, corporate and academic partners.”
Microba’s precision microbiome analysis capabilities will be on display in a free virtual event held 15 September 2021 titled “Driving new discovery with precision microbiome analysis and advanced AI” via Global Engage.